EGFR has been associated with increased malignancy in ovarian cancer [34, 35]; however, clinical trials using EGFR inhibitors as ovarian cancer treatments have had varying results, primarily due to recurrence and the lack of suitable biomarkers for predicting response to EGFR inhibition [36], highlighting a need to better understand what drives EGFR-mediated ovarian cancer malignancy. This evidence concerns the gene EGFR and ovarian carcinoma.